News

Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, “Autoimmunity and long-term safety and efficacy…

Being a lifelong musician can help protect certain tracts of the brain’s white matter from damage during aging, potentially warding off conditions such as multiple sclerosis, Parkinson’s disease, or dementia for years. That’s according to the study “Effects of Lifelong Musicianship on White Matter Integrity…

Adults with multiple sclerosis (MS) and depression or anxiety, especially those of minority groups, are being asked to join a clinical trial assessing the benefits of eSupport Health’s online support group program, the National MS Society announced in a press release. The CONNECT study is particularly focused on Black and…

Multiple Sclerosis News Today brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…

Cognition-targeting exercise, when combined with cognitive behavioral therapy (CBT) — a type of talk therapy — may further ease fatigue and other symptoms in people with multiple sclerosis (MS), a study found. The study, “The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized…

Vitamin D supplementation may improve quality of life in people with multiple sclerosis (MS), according to a literature review study. Because vitamin D deficiency is common in MS patients, these findings suggest that “supplementation should be applied at least in a dose that covers the recommended intake,” the researchers…

A higher dose of Copaxone (glatiramer acetate) given three times weekly over seven years led to sustainably lower relapse rates and slowed disability progression in multiple sclerosis (MS) patients, according to a long-term analysis of the GALA study. The higher dose — 40 mg/mL — was generally well-tolerated with no…

Note: This story was updated Jan. 12, 2022, to note that Ponvory is approved in the U.K. for people with relapsing forms of MS who have active disease, defined by clinical or imaging features. The National Institute for Health and Care Excellence (NICE) has recommended that Ponvory (ponesimod)…

Donations to the Multiple Sclerosis Society of Canada through the end of this year will be double matched, meaning each donation will go three times as far in supporting Canadians with multiple sclerosis (MS) and in advancing research into the disease. All donations received until midnight on Dec.

COVID-19 infection rates after widespread vaccination were significantly higher among multiple sclerosis (MS) patients on Ocrevus (ocrelizumab) or Gilenya (fingolimod) than in the general population, but not among MS patients given other immunosuppressive disease-modifying therapies (DMTs), a data study in England reports. While information on patients’ vaccination…

XRHealth, a virtual reality clinic that provides treatments in patients’ homes, has integrated Tobii‘s eye-tracking technology into its platform, which will let clinicians treat patients with multiple sclerosis (MS) and other neurological conditions. “We are excited to partner with Tobii — the leader in eye tracking —…

MS-STAT2, a clinical trial testing whether the cholesterol-lowering medication simvastatin might slow disability progression in secondary progressive multiple sclerosis (SPMS), has finished enrollment. A total of 964 people are now in the trial (NCT03387670), making it the largest progressive MS trial not run by a commercial…

People with multiple sclerosis (MS) living in the U.K. are now eligible to receive one of three new treatments for COVID-19 that are meant to prevent serious disease in at-risk populations who tested positive for the virus. First available under this plan were Regeneron and Roche’s antibody-based therapy…

Treatment with a newly discovered subset of regulatory B-cells (Bregs) — a type of immune cell that dampens immune responses — significantly reduced symptoms in a mouse model of multiple sclerosis (MS), a study shows. Similar effects were observed in a mouse model of uveitis, an inflammatory eye disease triggered…

People with a higher genetic risk for multiple sclerosis (MS) are significantly more likely to develop the disease at an earlier age, a large study found. Specifically, those with the highest genetic risk were on average five years younger at the time their symptoms started than those with the…

Cortrophin Gel (repository corticotropin injection), an injectable gel medication approved for acute flares in multiple sclerosis (MS) and other chronic autoimmune diseases, is now available through the AllianceRx Walgreens Prime specialty pharmacy to patients living in the U.S. First approved by the U.S. Food and Drug Administration (FDA)…

The National Institute for Health and Care Excellence (NICE) in England is set to again recommend against adding Fampyra (fampridine) to the list of medications available to multiple sclerosis (MS) patients with walking difficulties through the country’s national health service (NHS). The poor cost-effectiveness of Fampyra — sold…

Protxx and the University of Victoria are partnering to explore digital biomarkers for multiple sclerosis (MS) that may improve monitoring of disease progression, and facilitate more personalized care and a better quality of life. The digital biomarkers are based on motion vibrations picked up by Protxx’s wearable “phybrata”…

Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines for COVID-19, according to a new study. “Highlighting groups who have mounted an inadequate vaccine response has already been helpful in guiding who should receive…

Women with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) before conception have a greater risk of relapses and disability progression during pregnancy than those given moderate-efficacy or no DMTs, according to a systematic review of studies. Exclusive breastfeeding for at least two to four months, however,…

There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive corticosteroids for the treatment of multiple sclerosis (MS) and other diseases, according to a new review paper. “We found no evidence where it was a conclusive slam dunk that…

Fatigue management — whether through a symptom-specific self-management program or through general education regarding managing multiple sclerosis (MS) — may help people with MS in keeping fatigue levels stable in the long term, a recent study suggests. Indeed, the benefits of such programs were found to remain in effect…

The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeutics’ application seeking the approval of ublituximab as a treatment for people with relapsing forms of multiple sclerosis. An FDA’s decision is expected on or before Sept. 28. The agency is not currently planning to hold an…

Owning a dog, cat or other household pet during the ongoing COVID-19 pandemic has helped multiple sclerosis (MS) patients gain a better overall sense of their health and well-being, a single-site survey by mail of people in the U.K. reported. But pet-owning patients reported no significant improvements in their…

Leaders of the International Progressive MS Alliance have proposed a global research strategy to find better ways to care for people with progressive forms of multiple sclerosis (MS). They detailed their proposal in the paper, “Charting a global research strategy for progressive MS—An international progressive MS…

Visual disturbances are common in people with multiple sclerosis (MS), particularly among those with secondary progressive MS (SPMS), longer disease duration, and worse disability status, a new study has found. Yet, “visual complaints may occur in people with all types of MS, anytime along the disease course, and…

Children and young adults who spend more time outdoors in the sunshine are less likely to develop multiple sclerosis (MS), according to a new study, which suggests that sunshine might help to protect against the disease. “Advising regular time in the sun of at least 30 minutes daily especially…

An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with multiple sclerosis (MS), especially early on in the disease, a study in patients reports. The study, “Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study,”…

A new subset of type 3 innate lymphoid cells (ILC3s) — a type of immune cell known mostly for its anti-inflammatory and immunosuppressive effects in the gut — infiltrates the brain and promotes the abnormal immune attacks that drive multiple sclerosis (MS), according to a study in a mouse model…